Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Thiazolidinediones and the risk of edema: a meta-analysis.

Berlie HD, Kalus JS, Jaber LA.

Diabetes Res Clin Pract. 2007 May;76(2):279-89. Epub 2006 Oct 18.

PMID:
17055103
2.

Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis.

Pinelli NR, Cha R, Brown MB, Jaber LA.

Ann Pharmacother. 2008 Nov;42(11):1541-51. doi: 10.1345/aph.1L198. Epub 2008 Oct 28.

PMID:
18957626
3.

Thiazolidinediones and risk of heart failure in patients with or at high risk of type 2 diabetes mellitus: a meta-analysis and meta-regression analysis of placebo-controlled randomized clinical trials.

Hernandez AV, Usmani A, Rajamanickam A, Moheet A.

Am J Cardiovasc Drugs. 2011;11(2):115-28. doi: 10.2165/11587580-000000000-00000. Review.

PMID:
21294599
4.

Thiazolidinediones in type 2 diabetes: a cardiology perspective.

Khanderia U, Pop-Busui R, Eagle KA.

Ann Pharmacother. 2008 Oct;42(10):1466-74. doi: 10.1345/aph.1K666. Epub 2008 Sep 2. Review.

PMID:
18698014
5.
6.

Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years.

Grossman LD, Parlan G, Bailey AL, Yee G, Yu M, Chan JY.

Clin Ther. 2009 Jan;31(1):74-88. doi: 10.1016/j.clinthera.2009.01.004.

PMID:
19243708
7.

Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials.

Nagajothi N, Adigopula S, Balamuthusamy S, Velazquez-Cecena JL, Raghunathan K, Khraisat A, Singh S, Molnar J, Khosla S, Benatar D.

Am J Ther. 2008 Nov-Dec;15(6):506-11. doi: 10.1097/MJT.0b013e318167180c.

PMID:
19127132
8.

Risk of acute myocardial infarction in patients treated with thiazolidinediones or other antidiabetic medications.

Stockl KM, Le L, Zhang S, Harada AS.

Pharmacoepidemiol Drug Saf. 2009 Feb;18(2):166-74. doi: 10.1002/pds.1700.

PMID:
19109802
9.

Thiazolidinediones in patients with diabetes mellitus and heart failure : implications of emerging data.

Macfarlane DP, Fisher M.

Am J Cardiovasc Drugs. 2006;6(5):297-304. Review.

PMID:
17083264
10.

Cardiovascular risk of rosiglitazone: another perspective.

Waksman JC.

J Pharm Pharmacol. 2008 Dec;60(12):1573-82. doi: 10.1211/jpp.60.12.0002. Review.

PMID:
19000361
11.

The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.

Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.

Pharmacoepidemiol Drug Saf. 2007 May;16(5):504-12.

PMID:
17245800
12.

Risk of stroke with thiazolidinediones: a ten-year nationwide population-based cohort study.

Lu CJ, Sun Y, Muo CH, Chen RC, Chen PC, Hsu CY.

Cerebrovasc Dis. 2013;36(2):145-51. doi: 10.1159/000353679. Epub 2013 Sep 11.

PMID:
24029780
13.

Thiazolidinediones in patients with type 2 diabetes mellitus and heart failure.

Granberry MC, Hawkins JB, Franks AM.

Am J Health Syst Pharm. 2007 May 1;64(9):931-6. Review.

PMID:
17468147
14.

Pioglitazone and cardiovascular risk. A comprehensive meta-analysis of randomized clinical trials.

Mannucci E, Monami M, Lamanna C, Gensini GF, Marchionni N.

Diabetes Obes Metab. 2008 Dec;10(12):1221-38. doi: 10.1111/j.1463-1326.2008.00892.x. Epub 2008 May 26. Review.

PMID:
18505403
16.

Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.

Dahabreh IJ, Economopoulos K.

Clin Trials. 2008;5(2):116-20. doi: 10.1177/1740774508090212. Erratum in: Clin Trials. 2008;5(5):559. Economopoulos, K [added].

PMID:
18375649
17.

How safe is the use of thiazolidinediones in clinical practice?

Rizos CV, Elisaf MS, Mikhailidis DP, Liberopoulos EN.

Expert Opin Drug Saf. 2009 Jan;8(1):15-32. doi: 10.1517/14740330802597821 . Review.

PMID:
19236215
18.

Thiazolidinediones and cancer: results of a meta-analysis of randomized clinical trials.

Monami M, Dicembrini I, Mannucci E.

Acta Diabetol. 2014 Feb;51(1):91-101. doi: 10.1007/s00592-013-0504-8. Epub 2013 Jul 14.

PMID:
23851465
19.
20.

Effect of thiazolidinediones on skeletal health in women with Type 2 diabetes.

Schwartz AV, Sellmeyer DE.

Expert Opin Drug Saf. 2008 Jan;7(1):69-78. doi: 10.1517/14740338.7.1.69 . Review.

PMID:
18171315

Supplemental Content

Support Center